World Antimalarial Resistance Network (WARN) III

Molecular markers for drug resistant malaria

C Plowe, C Roper, J Barnwell, C Happi, H Joshi, Wilfred Mbacham, S Meshnick, K Mugittu, I Naidoo, Ric Price, R Shafer, C Sibley, Colin Sutherland, P Zimmerman, P Rosenthal

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Molecular markers for drug resistant malaria represent public health tools of great but mostly unrealized potential value. A key reason for the failure of molecular resistance markers to live up to their potential is that data on the their prevalence is scattered in disparate databases with no linkage to the clinical, in vitro and pharmacokinetic data that are needed to relate the genetic data to relevant phenotypes. The ongoing replacement of older monotherapies for malaria by new, more effective combination therapies presents an opportunity to create an open access database that brings together standardized data on molecular markers of drug resistant malaria from around the world. This paper presents a rationale for creating a global database of molecular markers for drug resistant malaria and for linking it to similar databases containing results from clinical trials of drug efficacy, in vitro studies of drug susceptibility, and pharmacokinetic studies of antimalarial drugs, in a World Antimalarial Resistance Network (WARN). This database will be a global resource, guiding the selection of first line drugs for treating uncomplicated malaria, for preventing malaria in travelers and for intermittent preventive treatment of malaria in pregnant women, infants and other vulnerable groups. Perhaps most important, a global database for molecular markers of drug resistant malaria will accelerate the identification and validation of markers for resistance to artemisinin-based combination therapies and, thereby, potentially prolong the useful therapeutic lives of these important new drugs. � 2007 Plowe et al; licensee BioMed Central Ltd.
Original languageEnglish
Pages (from-to)121-
JournalMalaria Journal
Volume6
Publication statusPublished - 2007

Fingerprint

Antimalarials
Malaria
Pharmaceutical Preparations
Chemical Databases
Databases
Pharmacokinetics
Therapeutics
Pregnant Women
Public Health
Clinical Trials
Phenotype

Cite this

Plowe, C., Roper, C., Barnwell, J., Happi, C., Joshi, H., Mbacham, W., ... Rosenthal, P. (2007). World Antimalarial Resistance Network (WARN) III: Molecular markers for drug resistant malaria. Malaria Journal, 6, 121-.
Plowe, C ; Roper, C ; Barnwell, J ; Happi, C ; Joshi, H ; Mbacham, Wilfred ; Meshnick, S ; Mugittu, K ; Naidoo, I ; Price, Ric ; Shafer, R ; Sibley, C ; Sutherland, Colin ; Zimmerman, P ; Rosenthal, P. / World Antimalarial Resistance Network (WARN) III : Molecular markers for drug resistant malaria. In: Malaria Journal. 2007 ; Vol. 6. pp. 121-.
@article{c43f054bc9e84b9390ffad22d72f6b99,
title = "World Antimalarial Resistance Network (WARN) III: Molecular markers for drug resistant malaria",
abstract = "Molecular markers for drug resistant malaria represent public health tools of great but mostly unrealized potential value. A key reason for the failure of molecular resistance markers to live up to their potential is that data on the their prevalence is scattered in disparate databases with no linkage to the clinical, in vitro and pharmacokinetic data that are needed to relate the genetic data to relevant phenotypes. The ongoing replacement of older monotherapies for malaria by new, more effective combination therapies presents an opportunity to create an open access database that brings together standardized data on molecular markers of drug resistant malaria from around the world. This paper presents a rationale for creating a global database of molecular markers for drug resistant malaria and for linking it to similar databases containing results from clinical trials of drug efficacy, in vitro studies of drug susceptibility, and pharmacokinetic studies of antimalarial drugs, in a World Antimalarial Resistance Network (WARN). This database will be a global resource, guiding the selection of first line drugs for treating uncomplicated malaria, for preventing malaria in travelers and for intermittent preventive treatment of malaria in pregnant women, infants and other vulnerable groups. Perhaps most important, a global database for molecular markers of drug resistant malaria will accelerate the identification and validation of markers for resistance to artemisinin-based combination therapies and, thereby, potentially prolong the useful therapeutic lives of these important new drugs. � 2007 Plowe et al; licensee BioMed Central Ltd.",
keywords = "amodiaquine, artemether plus benflumetol, artemisinin, artesunate, benflumetol, chloroquine, cotrimoxazole, mefloquine, molecular marker, piperaquine, antimalarial agent, clinical trial, combination chemotherapy, data base, development, drug efficacy, drug sensitivity, human, in vitro study, malaria, review, standardization, Trypanosoma vivax, validation study, world antimalarial resistance network, article, clinical trial (topic), drug combination, drug resistance, genetic marker, genetics, health, Internet, molecular epidemiology, sentinel surveillance, Antimalarials, Clinical Trials as Topic, Databases as Topic, Drug Resistance, Drug Therapy, Combination, Genetic Markers, Humans, Malaria, Molecular Epidemiology, Parasitic Sensitivity Tests, Sentinel Surveillance, World Health",
author = "C Plowe and C Roper and J Barnwell and C Happi and H Joshi and Wilfred Mbacham and S Meshnick and K Mugittu and I Naidoo and Ric Price and R Shafer and C Sibley and Colin Sutherland and P Zimmerman and P Rosenthal",
year = "2007",
language = "English",
volume = "6",
pages = "121--",
journal = "Malaria Journal",
issn = "1475-2875",
publisher = "BioMed Central",

}

Plowe, C, Roper, C, Barnwell, J, Happi, C, Joshi, H, Mbacham, W, Meshnick, S, Mugittu, K, Naidoo, I, Price, R, Shafer, R, Sibley, C, Sutherland, C, Zimmerman, P & Rosenthal, P 2007, 'World Antimalarial Resistance Network (WARN) III: Molecular markers for drug resistant malaria', Malaria Journal, vol. 6, pp. 121-.

World Antimalarial Resistance Network (WARN) III : Molecular markers for drug resistant malaria. / Plowe, C; Roper, C; Barnwell, J; Happi, C; Joshi, H; Mbacham, Wilfred; Meshnick, S; Mugittu, K; Naidoo, I; Price, Ric; Shafer, R; Sibley, C; Sutherland, Colin; Zimmerman, P; Rosenthal, P.

In: Malaria Journal, Vol. 6, 2007, p. 121-.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - World Antimalarial Resistance Network (WARN) III

T2 - Molecular markers for drug resistant malaria

AU - Plowe, C

AU - Roper, C

AU - Barnwell, J

AU - Happi, C

AU - Joshi, H

AU - Mbacham, Wilfred

AU - Meshnick, S

AU - Mugittu, K

AU - Naidoo, I

AU - Price, Ric

AU - Shafer, R

AU - Sibley, C

AU - Sutherland, Colin

AU - Zimmerman, P

AU - Rosenthal, P

PY - 2007

Y1 - 2007

N2 - Molecular markers for drug resistant malaria represent public health tools of great but mostly unrealized potential value. A key reason for the failure of molecular resistance markers to live up to their potential is that data on the their prevalence is scattered in disparate databases with no linkage to the clinical, in vitro and pharmacokinetic data that are needed to relate the genetic data to relevant phenotypes. The ongoing replacement of older monotherapies for malaria by new, more effective combination therapies presents an opportunity to create an open access database that brings together standardized data on molecular markers of drug resistant malaria from around the world. This paper presents a rationale for creating a global database of molecular markers for drug resistant malaria and for linking it to similar databases containing results from clinical trials of drug efficacy, in vitro studies of drug susceptibility, and pharmacokinetic studies of antimalarial drugs, in a World Antimalarial Resistance Network (WARN). This database will be a global resource, guiding the selection of first line drugs for treating uncomplicated malaria, for preventing malaria in travelers and for intermittent preventive treatment of malaria in pregnant women, infants and other vulnerable groups. Perhaps most important, a global database for molecular markers of drug resistant malaria will accelerate the identification and validation of markers for resistance to artemisinin-based combination therapies and, thereby, potentially prolong the useful therapeutic lives of these important new drugs. � 2007 Plowe et al; licensee BioMed Central Ltd.

AB - Molecular markers for drug resistant malaria represent public health tools of great but mostly unrealized potential value. A key reason for the failure of molecular resistance markers to live up to their potential is that data on the their prevalence is scattered in disparate databases with no linkage to the clinical, in vitro and pharmacokinetic data that are needed to relate the genetic data to relevant phenotypes. The ongoing replacement of older monotherapies for malaria by new, more effective combination therapies presents an opportunity to create an open access database that brings together standardized data on molecular markers of drug resistant malaria from around the world. This paper presents a rationale for creating a global database of molecular markers for drug resistant malaria and for linking it to similar databases containing results from clinical trials of drug efficacy, in vitro studies of drug susceptibility, and pharmacokinetic studies of antimalarial drugs, in a World Antimalarial Resistance Network (WARN). This database will be a global resource, guiding the selection of first line drugs for treating uncomplicated malaria, for preventing malaria in travelers and for intermittent preventive treatment of malaria in pregnant women, infants and other vulnerable groups. Perhaps most important, a global database for molecular markers of drug resistant malaria will accelerate the identification and validation of markers for resistance to artemisinin-based combination therapies and, thereby, potentially prolong the useful therapeutic lives of these important new drugs. � 2007 Plowe et al; licensee BioMed Central Ltd.

KW - amodiaquine

KW - artemether plus benflumetol

KW - artemisinin

KW - artesunate

KW - benflumetol

KW - chloroquine

KW - cotrimoxazole

KW - mefloquine

KW - molecular marker

KW - piperaquine

KW - antimalarial agent

KW - clinical trial

KW - combination chemotherapy

KW - data base

KW - development

KW - drug efficacy

KW - drug sensitivity

KW - human

KW - in vitro study

KW - malaria

KW - review

KW - standardization

KW - Trypanosoma vivax

KW - validation study

KW - world antimalarial resistance network

KW - article

KW - clinical trial (topic)

KW - drug combination

KW - drug resistance

KW - genetic marker

KW - genetics

KW - health

KW - Internet

KW - molecular epidemiology

KW - sentinel surveillance

KW - Antimalarials

KW - Clinical Trials as Topic

KW - Databases as Topic

KW - Drug Resistance

KW - Drug Therapy, Combination

KW - Genetic Markers

KW - Humans

KW - Malaria

KW - Molecular Epidemiology

KW - Parasitic Sensitivity Tests

KW - Sentinel Surveillance

KW - World Health

M3 - Article

VL - 6

SP - 121-

JO - Malaria Journal

JF - Malaria Journal

SN - 1475-2875

ER -

Plowe C, Roper C, Barnwell J, Happi C, Joshi H, Mbacham W et al. World Antimalarial Resistance Network (WARN) III: Molecular markers for drug resistant malaria. Malaria Journal. 2007;6:121-.